Ceftibuten: Current Role in the Therapy of Infections | CMAC

Ceftibuten: Current Role in the Therapy of Infections

Clinical Microbiology and Antimicrobial Chemotherapy. 2006; 8(4):368-382

​ Veselov A.V., Kozlov R.S.
cephalosporins ceftibuten communityacquired pneumonia sinusitis pharyngitis acute otitis media prostatitis
Section
Antimicrobials
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2006; 8(4):368-382

Abstract

Beta-lactams remain the most used class of antibiotics all over the world. Among them, cephalosporins occupy the leading place. This is due to not only wide spectrum of activity, but also a good tolerability of this antibiotic class. Оral therapy with beta-lactams is an integral part of therapy of nosocomial community-acquired infections and step-down therapy of nosocomial infections. This review presents clinical and pharmacological properties of the oral III gene­ration cephalosporin, ceftibuten, and an attempt to determine its place in the modern therapy of different infections.

  • 1. Kumazawa J., Yagisawa M. The history of antibiotics: The Japanese story. J Infect Chemother 2002; 8:125-33.
  • 2. Braga P.C., Piatti G. Kinetics of filamentation of Escherichia coli induced by different sub-MICs of ceftibuten at different times. Chemotherapy 1993; 39:272-7.
  • 3. Wise R., Andrews J.M., Ashby J.P., Thornber D. Ceftibuten: a new orally absorbed cephalosporin – in vitro activity against strains from the United Kingdom. Diagn. Microbiol. Infect Dis 1991; 14:45-52.
  • 4. Braga P.C., Piatti G., Dal Sasso M., et al. The in vitro effects of ceftibuten on the host defense mechanism. Chemotherapy 1994; 40:37-41.
  • 5. Bauernfeind A. Ceftibuten and bacterial kinetics: comparative in vitro activity against Enterobacteriaceae producing extended-spectrum beta-lactamases. Diagn Microbiol Infect Dis 1991; 14:89-92.
  • 6. Jones R.N., Barry A.L. Antimicrobial activity, spectrum and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S; SGH 39720), a new orally administered cephalosporin. Antimicrob Agents Chemother 1988; 32:1576-82.
  • 7. Craig W.A., Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996; 15:255-9.
  • 8. Barry A.L., Jones R.N., and the Collaborative Antimicrobial Susceptibility Testing Group. Interpretive criteria and quality control limits for ceftibuten disc susceptibili ty tests. J Clin Microbiol 1990; 28:605-7.
  • 9. Shawar R., LaRocco M., Cleary T.G. Comparative in vitro acti­vity of ceftibuten (Sch 39720) against bacterial enteropathogens. Antimicrob Agents Chemother 1989; 33:781-4.
  • 10. Liao C.H., Sheng W.H., Wang J.T., et al. In vitro activities of 16 antimicrobial agents against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in two regional hospitals in Taiwan. J Microbiol Immunol Infect 2006; 39:59-66.
  • 11. Wiseman L.R., Balfour J.A. Ceftibuten. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1994; 47:784-808.
  • 12. Bragman S.G.L., Casewell M.W. The in vitro activity of ceftibuten against 475 clinical isolates of gram-negative bacilli, compared with cefuroxime and cefadroxil. J Antimicrob Chemother 1990; 25:221-6.
  • 13. Jones R.N. Ceftibuten: a review of antimicrobial activity, spectrum and other microbiological features. Pediatr Infect Dis J 1995; 14(7 Suppl):S77-S83.
  • 14. Wise R., Andrews J.M., Ashby J.P., Thornber D. Ceftibuten – in vitro activity against respiratory pathogens, beta-lactamase stability and mechanism of action. J Antimicrob Chemother 1990; 26:209-13.
  • 15. Neu H.C. Ceftibuten: minimal inhibitory concentrations, post-antibiotic effect, beta-lactamase stability – a rationale for dosing programs. Pediatr Infect Dis J 1995; 14(7 Suppl):S88-92.
  • 16. Jones R.N., Barry A.L. In vitro evaluation of ceftibuten (7432-S, SCH 39720), a novel orally administered cephalosporin. Chemioterapia 1988; 7:283-6.
  • 17. Jones R.N., Barry A.L., The Collaborative Antimicrobial Susceptibility Testing Group. Ceftibuten (7432-S; SGH 39720): comparative antimicrobial activity against 4735 clinical isolates, beta-lactamase stability and broth microdilution quality control guidelines. Eur J Clin Microbiol Infect Dis 1988; 7:802-7.
  • 18. Verbist L., Jacobs J., Hens K. Comparative antimicrobial activity of ceftibuten against multiply-resistant micro­organisms from Belgium. Diagn Microbiol Infect Dis 1991; 14:53-61.
  • 19. Debbia E.A., Schito G.C., Pesce A. Antibacterial activity of ceftibuten, a new oral third generation cephalosporin. J Chemother 1991; 3:209-55.
  • 20. Doern G.V. In vitro activity of ceftibuten against Haemophilus influenzae and Branhamella catarrhalis. Diagn Microbiol Infect Dis 1991; 14:75-7.
  • 21. Jones R.N. Ceftibuten: a review of antimicrobial activity, spectrum and other microbiological features. Pediatr Infect Dis J 1995; 14(7 Suppl):S77-S83.
  • 22. Kitzis M.-D., Liassine N., Ferre В., et al. In vitro activities of 15 oral beta-lactams against Klebsiella pneumoniae harboring new extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1990; 34:1783-6.
  • 23. Bedenic B., Vranes J., Suto S., Zagar Z. Bactericidal activity of oral beta-lactam antibiotics in plasma and urine versus isogenic Escherichia coli strains producing broad- and extended-spectrum beta-lactamases. Int J Antimicrob Agents 2005; 25:479-87.
  • 24. Guerillot F., Garret G., Flandrois J.P. A statistical evaluation of the bactericidal effects of ceftibuten in combination with aminoglycosides and ciprofloxacin. J Antimicrob Chemother 1993; 32:685-94.
  • 25. Barr W.H., Affrime M., Lin C.-C., Batra V. Pharmacokinetics of ceftibuten in children. Pediatr Infect Dis J 1995; 14(7 Suppl):S93-101.
  • 26. Barr W.H., Lin C.C., Radwanski E., et al. The pharmacokinetics of ceftibuten in humans. Diagn Microbiol Infect Dis 1991; 14:93-100.
  • 27. Wise R., Nye K., O’Neill P., et al. Pharmacokinetics and tissue penetration of ceftibuten. Antimicrob Agents Chemother 1990; 34:1053-5.
  • 28. Scaglione F., Triscari F., Demartini G., et al. Concentrations of ceftibuten in bronchial secretions. Chemotherapy 1995; 41:229-33.
  • 29. Kelloway J.S., Awni W.M., Lin C.C., et al. Pharmacokinetics of ceftibuten-cis and its trans metabolite in healthy volunteers and in patients with chronic renal insufficiency. Antimicrob Agents Chemother 1991; 35:2267-74.
  • 30. Kearns G.L., Reed M.D., Jacobs R.F., et al. Singledose pharmacokinetics of ceftibuten (SCH 39720) in infants and children. Antimicrob Agents Chemother 1991; 35:2078-84.
  • 31. Bachmann K., Schwartz J., Jauregui L., et al. Failure of ceftibuten to alter single-dose theophylline clearance. J Clin Pharmacol 1990; 30:444-8.
  • 32. Radwanski E., Nomeir A., Cutler D., et al. Pharmacokinetic drug interaction study: administration of ceftibuten concurrently with the antacid Mylanta double-strength liquid or with ranitidine. Am J Ther 1998; 5:67-72.
  • 33. Reidenberg B.E. Worldwide safety experience with ceftibuten pediatric suspension. Pediatr Infect Dis J 1995; 14(7 Suppl):S130-3.
  • 34. Hashimoto H., Yamaguchi S., Yachiku S. Clinical studies of ceftibuten in the field of urology. Japan J Antibiotics 1990; 53:355-61.
  • 35. Muzutani S, Nishimura K., Yoshimura K., et al. Clinical experience with ceftibuten in complicated urinary tract infections. Japan J Antibiotics 1990; 53:779-89.
  • 36. Stein G.E., Christensen S., Mummaw N. Treatment of acute uncomplicated urinary tract infection with ceftibuten. Infection 1991; 19:124-6.
  • 37. Suzuki K., Nagata Y., Horiba M. Clinical studies on ceftibuten in the urinary field infection. Japan J Antibiotics 1990; 53:2003-10.
  • 38. Banfi A., Gabriele G., Hill-Juarez J.M., et al. Multinational comparative trial of ceftibuten and trimethoprim/ sulfamethoxazole in the treatment of children with complicated or recurrent urinary tract infections. Pediatr Infect Dis J 1993; 12(Suppl.):S84-S91.
  • 39. Biemond A., de Fijter C.W.H., Oe P.L., et al. Oral treatment of complicated urinary tract infections: Ceftibuten (Sch39720) versus trimethoprim-sulfamethoxazole (TMP-SMX). Nether J Med 1991; 39:A43.
  • 40. Kumazawa J., Matsumoto T., Kumamoto Y., et al. A double-blind comparative study of ceftibuten and cefaclor for the treatment of complicated urinary tract infections. Nishinihon J Urology 1990; 52:921-37.
  • 41. Ho M.-W., Wang F.-D., Fung C.-P., Liu C.-Y. Comparative study of ceftibuten and cefixime in the treatment of complicated urinary tract infections. J Microbiol Immunol Infect 2001; 34:185-9.
  • 42. Inamatsu T., Fukayama M., Kato A., et al. Pharmacokinetics and clinical evaluation of 7432-S (a new oral cephem) in elderly patients. Chemotherapy 1989; 37(Suppl.):217-30.
  • 43. Takasugi M., Matsumoto K., Shishido H., et al. Basic and clinical studies on 7432-S, a new oral cephem. Chemotherapy 1989; 37(Suppl. 1):298-313.
  • 44. Watanabe A., Oizumi K., Motomiya M., et al. Therapeutic efficacy of ceftibuten in chronic respiratory tract infections. Japan J Antibiotics 1990; 43:768-78.
  • 45. McCabe R., Rumans L., Perrotta R., Magabgad W. Comparison of the efficacy and safety of ceftibuten and cefaclor in the treatment of pneumonia and bronchiectasis. J Chemother 1993; 5:124-32.
  • 46. Nasu M., Saitoh A., Ohizumi K., et al. Comparative clinical study of 7432-S (ceftibuten) and cefaclor in chronic respiratory tract infections by a double-blind study. Chemotherapy 1989; (Suppl. A):A126.
  • 47. Blumer J.L., McLinn S.E., DeAbate C.A., et al. Multinational multicenter controlled trial comparing ceftibuten with cefaclor for the treatment of acute otitis media. Pediatr Infect Dis J 1995; 14(7 Suppl.):S115-20.
  • 48. McLinn S.E., McCarty J.M., Perrotta R., et al. Multicenter controlled trial comparing ceftibuten with amoxicillin/ clavulanic acid in the empiric treatment of acute otitis media. Pediatr Infect Dis J 1993; 12(Suppl.):S70-S76.
  • 49. Pichichero M.E., McLinn S.E., Gooch W.M., et al. Ceftibuten vs. penicillin V in group A beta-hemolytic streptococcal pharyngitis. Pediatr Infect Dis J 1995; 14(7 Suppl):S102-7.
  • 50. De Abate C.A., Perrott R.J., Dennington M.L., et al. The efficacy and safety of once-daily ceftibuten compared with co-amoxiclav in the treatment of acute bacterial sinusitis. J Chemother 1993; 4:358-63.
  • 51. Guest N., Langan C.E. Comparison of the efficacy and safety of a short course of ceftibuten with that of amoxycillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. Int J Antimicrob Agents 1998; 10:49-54.
  • 52. Adam D., Scholz H., Helmerking M. Five days ceftibuten versus 10 days penicillin in the treatment of 2099 patients with A-streptococcal tonsillopharyngitis. Fortschr Med Orig 2001; 119(Suppl 2):63-70.
  • 53. Bocazzi A., Tonelli P., Angelis M., et al. Short course therapy with ceftibuten versus azithromycin in pediatric streptococcal pharyngitis. Pediatr Infect Dis J 2000; 19:963-7.
  • 54. Drago L., Ripa S., Zampaloni C., et al. Activity of ceftibuten, cefaclor, azithromycin, clarithromycin, erythromycin and telithromycin against Streptococcus pyogenes clinical isolates with different genotypes and phenotypes. Chemotherapy 2005; 51:268-71.
  • 55. Sterkers O. Efficacy and tolerability of ceftibuten ver­sus amoxicillin/clavulanate in the treatment of acute sinusitis. Chemotherapy 1997; 43:352-7.
  • 56. Cho N., Fukunaga K., Kunii K., Kimura T. 7432-S in the obstetric and gynecological field. Chemotherapy 1989; 37(Suppl.):570-8.
  • 57. Yamamoto T., Yasuda J., Kanao M., Okada H. Basic and clinical studies on 7432-S in the field of obstetrics and gynecology. Chemotherapy 1989; 37(Suppl. 1):600-6.
  • 58. Matsuda S., Shimizu T., Maki M., et al. Comparative double-blind clinical trial of ceftibuten (7432-S) and bacampicillin (BAPC) against gynecological infections. Chemotherapy 1989; 37(Suppl. 1):667-700.
  • 59. Prado D., Lopez E., Liu H., et al. Ceftibuten and trimethoprim-sulfamethoxazole for treatment of Shigella and enteroinvasive Escherichia coli disease. Pediatr Infect Dis J 1992; 11:644-7.
  • 60. Moolasart P., Eampokalap B., Ratanasrithong M. Comparison of the efficacy of ceftibuten and norfloxacin in the treatment of acute gastrointestinal infection in children. Southeast Asian J Trop Med Public Health 1999; 30:764-9.
  • 61. Dubey A. K., Vidyashankar C., Bhata S. S., Sharma R. K. Ceftibuten in enteric fever. Indian Pediatrics 2000; 37:222.
  • 62. Chong L.Y., Cheung W.M., Leung C.S., et al. Clinical evaluation of ceftibuten in gonorrhea. A pilot study in Hong Kong. Sex Transm Dis 1998; 25:464-7.
  • 63. Data available from www.cedax.com.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared